Gene therapy is a beacon of hope for treating incurable genetic diseases, but most gene therapies rely on adeno-associated viral (AAV) vectors for their delivery. These viral carriers may trigger toxic immune responses and decrease gene therapy efficiency. In this seminar, four gene therapy experts will discuss the major hurdles of AAV-based gene therapy, including inefficient vector delivery, immunogenicity, and viral vector integration.
Topics to be covered
- Minimizing post-organ transplant complications with gene therapy
- Addressing the immune response to gene therapy
- Enhancing viral gene delivery and manufacturing using directed evolution and genetic selection
- Preventing AAVs from integrating into the genome
Thursday, June 29th, 2023 | 1:30 PM - 4:00 PM Eastern Time
This seminar will be available to view live and on demand.
Speakers
Dawn Bowles, PhD
Assistant professor
Duke University
Samira Kiani, MD, PhD
Associate Professor
University of Pittsburgh
David Schaffer, PhD
Hubbard Howe Jr. Distinguished Professor
University of California at Berkeley
Weidong Xiao, PhD
Professor
Indiana University
